Genmab(US:GMAB) Globenewswire·2025-09-03 12:30Core Insights - Genmab A/S announced updated results from the Phase 2 EPCORE NHL-6 trial evaluating the investigational epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in an outpatient setting [2][4] - The trial demonstrated the feasibility of outpatient treatment, with 92% of patients receiving the first full dose in this setting, and showed consistent safety and efficacy profiles compared to previous studies [3][4] Study Results - A total of 88 patients received the first full dose (48 mg) of epcoritamab, with 81 patients (92%) treated as outpatients [3] - The overall response rate (ORR) was 64.3% and the complete response (CR) rate was 47.6% in patients who had received one prior line of systemic therapy [4] - In patients treated after two or more lines of therapy, the ORR was 60.0% and the CR rate was 38.0% [4] Safety Profile - Cytokine release syndrome (CRS) occurred in 40.2% of patients during the trial, primarily low grade (Grade 1-2), with a median resolution time of two days [3] - Immune cell-associated neurotoxicity syndrome (ICANS) was observed in 7.6% of patients, also primarily low grade, resolving within a median of three days [3] Industry Context - DLBCL is the most common type of non-Hodgkin lymphoma, accounting for approximately 25-30% of all NHL cases, with around 25,000 new cases diagnosed annually in the U.S. [7][8] - The EPCORE NHL-6 trial results are significant as they suggest a shift towards outpatient treatment options for DLBCL patients, potentially increasing access to therapies [4]